Talk to many urologists and the axiom is “you are more likely to die with prostate cancer than from it”. This study was conducted on...
In this review, Klotz and Dall’Era summarise available data from the Toronto, UCSF, ERSPC, PASS and Royal Marsden active surveillance cohorts, looking specifically at outcomes...
With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to...
The market for bladder outflow obstruction surgery is currently wide open with new technologies such as Urolift® emerging. One of the key selling points of...
This article reviews active surveillance (AS) in the management of small renal masses (SRM), the role of renal tumour biopsy (RTB), patient selection, tumour growth...
There are a number of treatments now available to patients with metastatic castrate-resistant prostate cancer (mCRPC). However, the optimal timing and order in which they...
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also...
Of patients undergoing radiotherapy (RT) for prostate cancer (PC), at least 15-20% will experience recurrence. Although salvage prostatectomy achieves durable oncological outcomes at 10 years,...
All of us are involved in the teaching and training of under or postgraduate medical students and nurses. This article gives a patient’s perspective and...
Neutrophil-to-lymphocyte ratio has been shown to be a prognostic factor in a number of different cancers. This is one of the largest studies to date...
The authors test a hypothesis retrospectively in two cohorts of patients with non-muscle invasive bladder cancer (NMIBC), that endogenous bacteria in the bladder might exert...
Molecular imaging utilising prostate-specific membrane antigen (PSMA) as a target has increasingly been mentioned at key conferences and meetings. PSMA is a membrane metalloenzyme that...